Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) released its quarterly earnings data on Friday. The company reported $0.22 earnings per share (EPS) for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%.
Chugai Pharmaceutical Stock Performance
OTCMKTS CHGCY traded up $0.23 during trading on Friday, hitting $22.34. The stock had a trading volume of 173,071 shares, compared to its average volume of 242,217. Chugai Pharmaceutical has a 12 month low of $19.50 and a 12 month high of $34.84. The company’s 50-day moving average price is $23.46 and its two-hundred day moving average price is $26.43. The company has a market capitalization of $73.51 billion, a PE ratio of 24.82 and a beta of 0.59.
Analysts Set New Price Targets
CHGCY has been the topic of a number of research reports. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Chugai Pharmaceutical currently has an average rating of “Buy”.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.
Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.
Read More
- Five stocks we like better than Chugai Pharmaceutical
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
- Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
